Evidence map›Paper›PMID 41776114›Full record

ArticleAnnals of hematology2026

Transforming the treatment of Alpha-Thalassemia: a single-center retrospective study on hematopoietic stem cell transplantation in transfusion-dependent pediatric patients.

Lihua Huang, Zhenbin Wei, Gaohui Yang, Lianjin Liu, Zhongming Zhang, Hongwen Xiao, Zeyan Shi, Yibin Yao, Meiqing Wu, Lingyuan Pan and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Lihua Huang *Department of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Zhenbin Wei *Department of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Gaohui Yang *Department of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Lianjin LiuDepartment of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Zhongming ZhangDepartment of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Hongwen XiaoDepartment of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Zeyan ShiDepartment of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Yibin YaoDepartment of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Meiqing WuDepartment of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Lingyuan PanDepartment of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Wenqiang XieDepartment of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Zhaoping GanDepartment of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Beicai LiuDepartment of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Zhongqing LiDepartment of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Rui HuangDepartment of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Xuemei ZhouDepartment of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Yinghua ChenDepartment of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Yanye LiuDepartment of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Juan BinDepartment of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Zhaofang PanDepartment of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Huicheng HuangDepartment of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Yongrong LaiDepartment of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Rongrong LiuDepartment of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China. rong2liu@hotmail.com.
Lingling ShiDepartment of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hematopoietic stem cell transplantation (HSCT) is the only definitive cure for transfusion-dependent α-thalassemia, though comprehensive studies on its effectiveness are limited. In this retrospective study, we analyzed the clinical characteristics of 21 pediatric patients with transfusion-dependent α-thalassemia who underwent HSCT, all of whom received a standardized conditioning regimen consisting of busulfan, cyclophosphamide, fludarabine, and anti-thymocyte globulin. After a median follow-up of 25 months (range: 7–92 months), the two-year overall survival (OS) and event-free survival (EFS) rates were both 90.2% (95% CI: 66.2–97.4%), and the two-year graft-versus-host disease-free, relapse-free survival (GRFS) rate was 82.3% (95% CI: 52.6–94.3%). The transplant-related mortality rate at two years was 5.0% (95% CI: 0.7–30.0%), with no cases of graft failure observed. Among the 19 surviving patients, hemoglobin levels significantly increased compared to pre-transplant levels (p < 0.05), and all became transfusion-independent. Hematopoietic stem cell transplantation is a curative treatment for α-thalassemia. For patients with transfusion-dependent α-thalassemia, HSCT should be performed as early as possible at an experienced transplant center when a suitable donor is available.

Indexed as

alpha-ThalassemiaBlood TransfusionHematopoietic Stem Cell TransplantationTransplantation ConditioningAdolescentAntilymphocyte SerumBusulfanChildChild, PreschoolCyclophosphamideDisease-Free SurvivalFemaleFollow-Up StudiesGraft vs Host DiseaseHumansInfantAntilymphocyte SerumBusulfanCyclophosphamideVidarabineAlpha-ThalassemiaGraft-versus-host diseaseHematopoietic stem cell transplantationtransfusion-dependent

Identifiers

PMID41776114
PMCPMC12957040

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.